Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation & Amortization - Total (2022 - 2025)

Historic Depreciation & Amortization - Total for InMed Pharmaceuticals (INM) over the last 4 years, with Q2 2025 value amounting to $12206.0.

  • InMed Pharmaceuticals' Depreciation & Amortization - Total rose 12437.5% to $12206.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $36618.0, marking a year-over-year decrease of 2289.0%. This contributed to the annual value of $50204.0 for FY2025, which is 515.69% up from last year.
  • According to the latest figures from Q2 2025, InMed Pharmaceuticals' Depreciation & Amortization - Total is $12206.0, which was up 12437.5% from $12203.0 recorded in Q1 2025.
  • InMed Pharmaceuticals' Depreciation & Amortization - Total's 5-year high stood at $14242.0 during Q4 2023, with a 5-year trough of $5440.0 in Q2 2024.
  • Over the past 4 years, InMed Pharmaceuticals' median Depreciation & Amortization - Total value was $12209.0 (recorded in 2024), while the average stood at $11773.0.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Depreciation & Amortization - Total tumbled by 5788.17% in 2024, and later soared by 12437.5% in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Depreciation & Amortization - Total (Quarter) stood at $8056.0 in 2022, then surged by 76.79% to $14242.0 in 2023, then fell by 14.27% to $12209.0 in 2024, then fell by 0.02% to $12206.0 in 2025.
  • Its last three reported values are $12206.0 in Q2 2025, $12203.0 for Q1 2025, and $12209.0 during Q4 2024.